5440672025-07-012025-09-305440672025-09-305440672025-03-315440672025-04-012025-09-305440672025-07-012025-09-30in-capmkt:OtherExpenses1Member5440672025-07-012025-09-30in-capmkt:OtherExpenses2Member5440672025-07-012025-09-30in-capmkt:OtherExpenses3Member5440672025-07-012025-09-30in-capmkt:OtherExpenses4Member5440672025-07-012025-09-30in-capmkt:OtherExpenses5Member5440672025-07-012025-09-30in-capmkt:OtherExpenses6Member5440672025-07-012025-09-30in-capmkt:OtherExpenses7Member5440672025-07-012025-09-30in-capmkt:OtherExpenses8Member5440672025-07-012025-09-30in-capmkt:OtherExpenses9Member5440672025-07-012025-09-30in-capmkt:OtherExpenses10Member5440672025-04-012025-09-30in-capmkt:OtherExpenses1Member5440672025-04-012025-09-30in-capmkt:OtherExpenses2Member5440672025-04-012025-09-30in-capmkt:OtherExpenses3Member5440672025-04-012025-09-30in-capmkt:OtherExpenses4Member5440672025-04-012025-09-30in-capmkt:OtherExpenses5Member5440672025-04-012025-09-30in-capmkt:OtherExpenses6Member5440672025-04-012025-09-30in-capmkt:OtherExpenses7Member5440672025-04-012025-09-30in-capmkt:OtherExpenses8Member5440672025-04-012025-09-30in-capmkt:OtherExpenses9Member5440672025-04-012025-09-30in-capmkt:OtherExpenses10Member5440672025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25440672025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares544067INNOVACAPNOTLISTEDINE0DUT01020INNOVA CAPTAB LIMITEDMain BoardEquity2025-04-012026-03-312025-11-072025-10-30INRMillionsQuarterlySecond quarterSingle segmentDrugs and Pharmaceutical products2025-11-0715:00:002025-11-0716:33:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated380381000041930000384574000023394500005647000039910000417150000549500001132200004322400003453390000392350000039235000055090000405600009565000002967000000000296700000-4610000292090000572250000105.185.18005.185.18The above consolidated financial results of Innova Captab Limited and its subsidiaries Holding and its subsidiaries together referred to as the Group have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Regulations 2015 as amended The results for the quarter and half year ended 30 September 2025 are available on the Company website under investor information section and on the stock exchange website <BR> The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 November 2025 The Board of Directors at their meeting held on 07 November 2025 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the consolidated financial results for the quarter and half year ended 30 September 2025 The Group comprise the following entities all of which have been incorporated in India <BR> Innova Captab Limited Holding Company <BR> Univentis Medicare Limited Subsidiary Company <BR> Sharon Bio-Medicine Limited Subsidiary Company <BR> Univentis Foundation Subsidiary <BR> <BR> The Group has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group2025-04-012025-09-30UnauditedConsolidated73192300008676000074059900004633890000106940000-9762000080805000083550000223670000828390000658687000081912000008191200001178400009443000021227000006068500000000606850000-45700006022800005722500001010.610.60010.610.6Power and fuel103580000Stores and spares consumed42860000Packing charges46460000Repairs and maintenance32750000Travelling and conveyance34430000Commission on sales28100000Freight charges25000000House keeping expense15670000Rates, fees and taxes15470000Miscellaneous expenses87920000Power and fuel197530000Stores and spares consumed92230000Packing charges86840000Repairs and maintenance63390000Travelling and conveyance63370000Commission on sales54080000Freight charges43520000House keeping expense30160000Rates, fees and taxes28940000Miscellaneous expenses16833000082959900007322000001669400007370000000005130000273900003252000055270000148990000878030000023585000000394942000053900005789600007940000489100000503081000007309600008120270000208100000169213800005722500009639170000102114200001021142000023043200000000230432000011391000015767000000257590000010604300003082000025668300002597650000276430000393451000012409000039480000359800000413406000000670996000016921380000Property plant and equipment includes amount of right of use of assets <BR> Borrowings non current include amount of lease liabilities <BR> Other non-current financial assets include amount of other tax assets netThe Company has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 201383550000-288750000-6254700000-179960000-100800000-14756000005945900000-55030000430000223670000-296000059000000263600000-7480000000000053800000-37741000044171000000-2097000012355000002971900000000000061510000422530000000000000000000000199000004290000-3547400000000000012588000013291000000844400000-780000-92250000-1498000000-1498000001551900005390000Remeasurement of defined benefit obligation-6210000Income tax relating to items that will not be reclassified to profit or loss1600000-4610000Remeasurement of defined benefit obligation-6120000Income tax relating to items that will not be reclassified to profit or loss1550000-457000000-4610000-4570000